Iovance Biotherapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 557
- Market Cap
- $3.4B
- Website
- http://www.iovance.com
- Introduction
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patient...
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
- Conditions
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03083873
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธUniversity of California, Los Angeles, Los Angeles, California, United States
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02360579
- Locations
- ๐บ๐ธ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
๐ฌ๐งRoyal Marsden NHS Trust, London, England, United Kingdom
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States